Passa al contenuto
Merck

Comparison of partial volume effects in arterial and venous contrast curves in CT brain perfusion imaging.

PloS one (2014-05-27)
Alan J Riordan, Edwin Bennink, Jan Willem Dankbaar, Max A Viergever, Birgitta K Velthuis, Ewoud J Smit, Hugo W A M de Jong
ABSTRACT

In brain CT perfusion (CTP), the arterial contrast bolus is scaled to have the same area under the curve (AUC) as the venous outflow to correct for partial volume effects (PVE). This scaling is based on the assumption that large veins are unaffected by PVE. Measurement of the internal carotid artery (ICA), usually unaffected by PVE due to its large diameter, may avoid the need for partial volume correction. The aims of this work are to examine i) the assumptions behind PVE correction and ii) the potential of selecting the ICA obviating correction for PVE. The AUC of the ICA and sagittal sinus were measured in CTP datasets from 52 patients. The AUCs were determined by i) using commercial CTP software based on a Gaussian curve-fitting to the time attenuation curve, and ii) by simple integration of the time attenuation curve over a time interval. In addition, frames acquired up to 3 minutes after first bolus passage were used to examine the ratio of arterial and venous enhancement. The impact of selecting the ICA without PVE correction was illustrated by reporting cerebral blood volume (CBV) measurements. In 49 of 52 patients, the AUC of the ICA was significantly larger than that of the sagittal sinus (p = 0.017). Measured after the first pass bolus, contrast enhancement remained 50% higher in the ICA just after the first pass bolus, and 30% higher 3 minutes later. CBV measurements were significantly lowered when the ICA was used without PVE correction. Contradicting the assumptions underlying PVE correction, contrast in the ICA was significantly higher than in the sagittal sinus, even 3 minutes after the first pass of the contrast bolus. PVE correction might lead to overestimation of CBV if the CBV is calculated using the AUC of the time attenuation curves.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Iopromide, European Pharmacopoeia (EP) Reference Standard
Iopromide for system suitability 1, European Pharmacopoeia (EP) Reference Standard
Iopromide for system suitability 2, European Pharmacopoeia (EP) Reference Standard